| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG. |
|
Medicine details |
|
| Medicine name | human normal immunoglobulin (HyQvia®) |
| Formulation | 100 mg/ml solution for infusion |
| Reference number | 1365 |
| Indication | Replacement therapy in adults, children and adolescents (0-18 years) in: primary immunodeficiency syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated; hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients, hypogammaglobulinaemia in patients pre- and post-allogeneic hematopoietic stem cell transplantation (HSCT) |
| Company | Takeda UK Ltd |
| BNF chapter | Immunological products & vaccines |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 25/10/2021 |